CME credits: 0.25

Valid until: 01-10-2021

Claim your CME credit at https://reachmd.com/programs/cme/late-breaking-data-in-moderate-to-severe-atopic-dermatitis/11797/

Statement of Need
Recent investigations into the underlying mechanisms of atopic dermatitis have revealed the importance of the JAK/STAT pathway and downstream cytokines in driving inflammatory response and AD pathogenesis and have informed the recent development of novel targeted agents. The recent and rapid emergence of new data on novel targeted treatments for moderate-to-severe AD creates a knowledge gap for dermatologists and allergists. These clinicians need to be familiar with the characteristics and latest data associated with targeted agents in clinical development for the treatment of moderate-to-severe AD so that they are prepared to rapidly integrate the agents into clinical practice as they become available.